The show that helps you maximize your wealth by turning complex financial situations into actionable advice. On Your Money. Your Mission., we answer the questions you’ve been asking about -- financial planning, investing, retirement and everything in between. Whether you’re navigating the complexities of the market or looking for the best ways to save or spend your money, tune in to hear from experienced financial advisors with JFG. Walk away from each episode with savvy tips and financial t ...
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Sona Nanotech clears Endotoxin testing, preps for first-in-human Gold Nanorod trial
MP3•Episode home
Manage episode 484068846 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Sona Nanotech Inc chief medical officer Dr Carman Giacomantonio joined Steve Darling from Proactive to announce a critical advancement as the company prepares for its first-in-human clinical study. Sona has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods using the Limulus Amebocyte Lysate (LAL) method, a widely accepted industry standard for evaluating medical and pharmaceutical products. The testing was conducted at a GLP-accredited U.S. laboratory operated by a leading global provider of MedTech and pharmaceutical testing services. The results showed that all tested samples passed with endotoxin levels below detection limits, ensuring that Sona's nanorods meet stringent safety standards. In addition, Positive Product Controls confirmed the test’s validity, with recovery values between 98% and 130%, indicating no assay interference—a further validation of the product’s safety profile. The EFS, which is pending ethics committee approval, is expected to begin patient enrollment and first dosing early this summer. The study will utilize the same batch of gold nanorods that passed the endotoxin screening, reinforcing confidence in the material's clinical readiness. With its novel biocompatible nanotechnology platform, Sona is pioneering a new generation of targeted medical therapies. This latest development places the company a step closer to clinical validation and eventual commercialization of its proprietary nanomaterials. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTreatment #MedicalInnovation #HyperthermiaTherapy #GoldNanoparticles #Immunotherapy #TargetedTherapy #CancerResearch #Biotech #MedicalBreakthrough #GoldNanorods
…
continue reading
606 episodes
MP3•Episode home
Manage episode 484068846 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Sona Nanotech Inc chief medical officer Dr Carman Giacomantonio joined Steve Darling from Proactive to announce a critical advancement as the company prepares for its first-in-human clinical study. Sona has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods using the Limulus Amebocyte Lysate (LAL) method, a widely accepted industry standard for evaluating medical and pharmaceutical products. The testing was conducted at a GLP-accredited U.S. laboratory operated by a leading global provider of MedTech and pharmaceutical testing services. The results showed that all tested samples passed with endotoxin levels below detection limits, ensuring that Sona's nanorods meet stringent safety standards. In addition, Positive Product Controls confirmed the test’s validity, with recovery values between 98% and 130%, indicating no assay interference—a further validation of the product’s safety profile. The EFS, which is pending ethics committee approval, is expected to begin patient enrollment and first dosing early this summer. The study will utilize the same batch of gold nanorods that passed the endotoxin screening, reinforcing confidence in the material's clinical readiness. With its novel biocompatible nanotechnology platform, Sona is pioneering a new generation of targeted medical therapies. This latest development places the company a step closer to clinical validation and eventual commercialization of its proprietary nanomaterials. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTreatment #MedicalInnovation #HyperthermiaTherapy #GoldNanoparticles #Immunotherapy #TargetedTherapy #CancerResearch #Biotech #MedicalBreakthrough #GoldNanorods
…
continue reading
606 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.